Stockscreener 앱 받기
2.29
1.29%
-0.03
Kiora Pharmaceuticals Inc 주식(KPRX)의 최신 뉴스
Kiora Pharmaceuticals (KPRX) Slips 0.43% to $2.34 as Shares Test Lower End of Recent RangeMoney Flow Index - https://www.dars.gov.et/
Kiora Pharmaceuticals (KPRX) Slips 0.43% to $2.34 as Shares Test Lower End of Recent RangeStock News - https://www.dars.gov.et/
Kiora Pharmaceuticals Inc (NASDAQ: KPRX) Stock Price, News & Analysis - kalkine.ca
Kiora Pharmaceuticals Inc (NYSE: KPRX) Stock Price, News & Analysis - Kalkine
KPRX Q2 2026 Earnings: Loss Narrows Past Estimates, but Shares Slide on Pre-Revenue ProfileFinancial Health Score - dars.gov.et
KPRX Q2 2026 Earnings: Loss Narrows Past Estimates, but Shares Slide on Pre-Revenue Profile - www.dars.gov.et
KPRX Q2 2026 Earnings: Loss Narrows Past Estimates, but Shares Slide on Pre-Revenue ProfileEarnings Cycle Outlook - www.dars.gov.et
New investor crosses 5% ownership in Kiora Pharmaceuticals (NASDAQ: KPRX) - Stock Titan
Kiora Pharmaceuticals names Keith Lane clinical development head By Investing.com - Investing.com Canada
Kiora Pharmaceuticals names Keith Lane clinical development head - Investing.com
Kiora Pharmaceuticals names Keith Lane clinical development head By Investing.com - Investing.com India
Kiora hires an executive who oversaw more than 60 eye-drug trials - Stock Titan
Kiora Pharmaceuticals names Keith Lane clinical development head By Investing.com - Investing.com Nigeria
KPRX 8-K & SEC FilingsYahoo Finance - Yahoo! Finance Canada
KPRX Q2 2026 Earnings: Narrower Loss Beats Estimates, Stock Still Slips 1.5%Earnings Miss Streak - dars.gov.et
KPRX Q2 2026 Earnings: Narrower Loss Beats Estimates, Stock Still Slips 1.5%Trough Earnings Signal - dars.gov.et
Chong Kun Dang Wins Korean Rights to Kiora Retinal Drug - Seoul Economic Daily
Kiora licenses KIO-301 rights in South Korea - grafa.com
Kiora Licenses South Korean KIO-301 Rights for $1M Upfront - Minichart
Kiora PharmaceuticalsEligible for Double D - Moomoo
Form 8K Kiora Pharmaceuticals Inc For: 19 August By Investing.com - Investing.com Nigeria
Kiora Licenses KIO-301 Rights in South Korea - TipRanks
Form 8K Kiora Pharmaceuticals Inc For: 19 August By Investing.com - Investing.com Australia
Form 8K Kiora Pharmaceuticals Inc For: 19 August By Investing.com - Investing.com Australia
Form 8K Kiora Pharmaceuticals Inc For: 19 August By Investing.com - Investing.com UK
Kiora Pharmaceuticals Licenses KIO-301 South Korea Rights to Chong Kun Dang for $1 Million Upfront Plus Milestones and Royalties - kalkine.ca
10,000-plus in South Korea are estimated to have a rare retinal disease; Kiora licenses KIO-301 - Stock Titan
Kiora Pharmaceuticals Inc (NASDAQ: KPRX) Stock Price, News & Analysis - Kalkine
Perceptive Advisors LLC Acquires New Position in Kiora Pharmaceuticals Inc (KPRX) - GuruFocus
ADAR1 group discloses 9.9% Kiora Pharmaceuticals (KPRX) stake via shares and warrants - Stock Titan
Nantahala Capital discloses 9.99% Kiora Pharmaceuticals (KPRX) stake via 13G/A filing - Stock Titan
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance
KPRX Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesReturn On Capital - Vinanet
Kiora Pharmaceuticals (KPRX) Rises 1.55% as Biotech Stock Holds Key Support at $2.49Regression Channel - dars.gov.et
Kiora Pharmaceuticals (KPRX) reports 9.99% stake held by Perceptive group - Stock Titan
Form 8K Kiora Pharmaceuticals Inc For: 7 August By Investing.com - Investing.com Nigeria
Kiora Pharmaceuticals advances retinal disease trials, secures $24M funding, expects data in 2027 - Pluang
Form 8K Kiora Pharmaceuticals Inc For: 7 August By Investing.com - Investing.com Canada
Kiora Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Kiora Pharmaceuticals Reports Q2 2026 Results, Advances KIO-301 and KIO-104 Trials With Runway Into Late 2028 - kalkine.ca
Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update - TMX Newsfile
Kiora Pharmaceuticals (KPRX) Gains 2.83% as Shares Approach $2.67 ResistanceGap and Reverse - dars.gov.et
Kiora Pharmaceuticals (KPRX) Gains 2.83% as Shares Approach $2.67 ResistanceOBV Divergence - dars.gov.et
Kiora Pharmaceuticals, Inc. expected to post a loss of 62 cents a shareEarnings Preview - TradingView
Kiora Pharmaceuticals Inc (KPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kiora Pharmaceuticals Market Sentiment - Benzinga España
Kiora Pharmaceuticals Inc (KPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
KPRX|Kiora Pharmaceuticals Inc|Price:2.530|Chg%:-0.020 - TradingKey
TradingKey - TradingKey
Kiora Pharmaceuticals Market Sentiment - Benzinga
3.09%
0.72%
자본화:
|
볼륨(24시간):